Motyl T, Traczyk Z, Cieśluk S, Daniewska-Michalska D, Kukulska W, Kałuzny Z, Podgurniak M, Orzechowski A, Debski B
Department of Animal Physiology, Faculty of Veterinary Medicine, Warsaw Agricultural University, Poland.
Eur J Clin Chem Clin Biochem. 1993 Nov;31(11):765-71. doi: 10.1515/cclm.1993.31.11.765.
The blood plasma concentration of pseudouridine was estimated in 104 healthy adult subjects, and 108 patients suffering from malignant proliferative diseases. The HPLC method for simultaneous determination of pseudouridine and creatinine was applied. The average physiological concentration of pseudouridine in blood plasma was 2.43 +/- 0.97 mumol.l-1 or 29.15 +/- 7.40 mmol.mol-1 creatinine. The physiological urinary excretion of pseudouridine was 14.32 +/- 5.20 mumol.24 h-1.kg-0.75 or 19.60 +/- 5.22 mmol.mol-1 creatinine. Renal clearance of pseudouridine and endogenous creatinine were 4.04 +/- 0.99 and 5.50 +/- 1.46 ml.kg-0.75, respectively. A positive correlation (r = 0.55, P < 0.01) was found between age (in the range 20-92 years) and blood plasma pseudouridine concentration (mumol.l-1). By expressing plasma pseudouridine in relation to plasma creatinine, the apparent influence of non-metabolic factors (age, renal insufficiency, blood dilution) on the plasma pseudouridine concentration were largely excluded. Among haematological proliferative diseases the highest values of plasma pseudouridine concentrations were observed in chronic lymphocytic leukaemia (8.19 mumol.l-1; 54.9 mmol.mol-1 creatinine) and multiple myeloma (7.02 mumol.l-1; 52.5 mmol.mol-1 creatinine). In multiple myeloma, but not in chronic lymphocytic leukaemia, the plasma pseudouridine concentration depended on the clinical stage. A lower, but still significant response in non-Hodgkin's lymphoma was noted (4.03 mumol.l-1; 40.88 mmol.mol-1 creatinine). A significant increase of the plasma pseudouridine concentration was characteristic of adenocarcinomas of the large intestine, and it occurred in the early stages of malignant growth. In patients with lung cancer the plasma pseudouridine concentration was elevated only in advanced cases with metastases.(ABSTRACT TRUNCATED AT 250 WORDS)
在104名健康成年受试者和108名患有恶性增殖性疾病的患者中估算了血浆中假尿苷的浓度。采用高效液相色谱法同时测定假尿苷和肌酐。血浆中假尿苷的平均生理浓度为2.43±0.97μmol·L⁻¹或29.15±7.40μmol·mol⁻¹肌酐。假尿苷的生理尿排泄量为14.32±5.20μmol·24 h⁻¹·kg⁻⁰.⁷⁵或19.60±5.22μmol·mol⁻¹肌酐。假尿苷和内源性肌酐的肾清除率分别为4.04±0.99和5.50±1.46 ml·kg⁻⁰.⁷⁵。在年龄（20 - 92岁）和血浆假尿苷浓度（μmol·L⁻¹）之间发现正相关（r = 0.55，P < 0.01）。通过将血浆假尿苷与血浆肌酐相关联来表示，非代谢因素（年龄、肾功能不全、血液稀释）对血浆假尿苷浓度的明显影响在很大程度上被排除。在血液系统增殖性疾病中，血浆假尿苷浓度的最高值出现在慢性淋巴细胞白血病（8.19μmol·L⁻¹；54.9μmol·mol⁻¹肌酐）和多发性骨髓瘤（7.02μmol·L⁻¹；52.5μmol·mol⁻¹肌酐）中。在多发性骨髓瘤中，但在慢性淋巴细胞白血病中并非如此，血浆假尿苷浓度取决于临床分期。在非霍奇金淋巴瘤中观察到较低但仍显著的反应（4.03μmol·L⁻¹；40.88μmol·mol⁻¹肌酐）。血浆假尿苷浓度显著升高是大肠腺癌的特征，且发生在恶性生长的早期阶段。在肺癌患者中，血浆假尿苷浓度仅在有转移的晚期病例中升高。（摘要截断于250字）
